title: The kallikrein/kinin system in the pathogenesis of hypertension in diabetes mellitus.
abstract: Essential hypertension (EH) is frequently not only a coexistent, but a preexistent condition in type-II-diabetes mellitus (NIDDM). Possible reasons for this phenomenon include the presence of the insulin resistance/hyperinsulinaemia syndrome in EH, leading to sodium retention, stimulation of the sympathetic nervous system and impaired glucose tolerance. Another reason could be a defect in the kallikrein-kinin system (KKS) which is known to be involved in both the regulation of blood pressure and insulin sensitivity of peripheral tissues. The classical concept of the glandular KKS as being an endocrine system with circulating hormones causing increased renal and peripheral blood flow, hypotension and natriuresis has changed recently, since kallikrein-like activity or mRNA coding for tissue kallikreins were detected in various tissues including kidney, vascular wall and skeletal muscle. This led to the present view, that paracrine local actions of different tissue KKS on regional blood flow, local substrate metabolism and insulin action are probably more important than previously expected. A disorder in the activity of the renal KKS has been known to be present in both NIDDM and EH. Recent work yielded evidence, that skeletal muscle KKS is activated upon muscle work in metabolically healthy subjects, but not in NIDDM and not in the majority of patients with EH. This suppressed tissue KKS seems to be a common feature of EH and NIDDM and might be involved in the pathogenesis of insulin resistance, impaired glucose tolerance and hypertension.
authors.affiliation: Dr. M. Wicklmayr II. Med. Abtzg. Schwabinger Krankenhains, München, FRG.
authors.forename: M
authors.initials: M
authors.lastname: Wicklmayr
authors.forename: K
authors.initials: K
authors.lastname: Rett
authors.forename: H
authors.initials: H
authors.lastname: Baldermann
authors.forename: G
authors.initials: G
authors.lastname: Dietze
mesh_terms: D000596:Amino Acids / Q000378:metabolism; D001920:Bradykinin / Q000494:pharmacology; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000503:physiopathology*; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000503:physiopathology*; D007328:Insulin / Q000494:pharmacology; D007610:Kallikreins / Q000502:physiology*; D007705:Kinins / Q000502:physiology*; D009132:Muscles / Q000098:blood supply / Q000187:drug effects / Q000378:metabolism; D010208:Papaverine / Q000494:pharmacology; D012016:Reference Values; D012039:Regional Blood Flow / Q000187:drug effects
chemical_list: D000596:Amino Acids; D007328:Insulin; D007705:Kinins; D010208:Papaverine; D007610:Kallikreins; D005947:Glucose; D001920:Bradykinin